2026 HCPR28 Heart Failure (HF): SGLT-2 Inhibitor Therapy for Left Ventricular Systolic Dysfunction (LVSD)

Measure Title: Heart Failure (HF): SGLT-2 Inhibitor Therapy for Left Ventricular Systolic Dysfunction (LVSD)

Description: Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) less than or equal to 40% who were prescribed SGLT-2 Inhibitors during their SNF stay or at the time of discharge.

Denominator: Any patient greater than or equal to 18 years of age evaluated by the Eligible Professional AND diagnosis of heart failure AND left ventricular ejection fraction (LVEF) less than or equal to 40% or documentation of moderately or severely depressed left ventricular systolic function

Denominator Exclusions:

Transferred, eloped, AMA, or expired patients are excluded; Discharged to hospice; Patients with history of heart transplant or with a Left Ventricular Assist Device (LVAD); Diabetic Ketoacidosis (DKA); Type 1 diabetes

Numerator:

Adult patients who were prescribed or currently taking SGLT-2 inhibitor therapy during SNF stay or at time of hospital discharge

Note: The numerator action applies per performance year. Once an SGLT-2 inhibitor has been identified as either a current medication, or is ordered, subsequent visits within the performance year do not need to be repeated to meet the measure. The evaluation of the numerator can be done anytime during the hospitalization or SNF stay, however certain CPT codes may only be applicable to discharge encounters.

National Quality Forum (NQF) number, if applicable

N/A

Care setting(s)

Hospital; Hospital Inpatient; Post Acute Care

Telehealth, if applicable
Yes

Number of performance rates required for measures
1

Traditional vs. inverse measure
Traditional

Proportional, continuous variable, and/or ratio measure indicator
Proportional

Risk adjustment, if applicable
No

Submission pathway
Traditional MIPS